Clinical Trials for Colon Cancer

A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants With Advanced or Metastatic Select Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls previously treated patients with unresectable locally advanced, recurrent, or metastatic NSCLC, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, or left-sided colorectal cancer; prior treatment with a topoisomerase I inhibitor–payload ADC is excluded. All participants receive ALX2004, an investigational EGFR-targeting antibody–drug conjugate with a topoisomerase I inhibitor payload, at a dose determined by the study stage.

ClinicalTrials.gov ID: NCT07085091

A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, locally advanced or metastatic KRAS-mutant or KRAS-amplified solid tumors who have no remaining standard treatment options or have declined them receive oral AMG 410, a reversible pan-KRAS inhibitor, alone or with the PD-1 inhibitor pembrolizumab. Patients with colorectal or pancreatic cancer may receive AMG 410 with the EGFR-targeting antibody panitumumab.

ClinicalTrials.gov ID: NCT07094113

An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable metastatic melanoma, colorectal cancer, pancreatic ductal adenocarcinoma, or head and neck squamous cell carcinoma harboring selected MAPK-pathway mutations, ECOG 0–1, and no suitable standard therapy receive oral IPN01194 monotherapy. IPN01194 inhibits ERK1/2, downstream components of MAPK signaling.

ClinicalTrials.gov ID: NCT06305247

A Phase 1/2a First-In-Human, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CT3001 in Patients with Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, unresectable locally advanced or metastatic solid tumors after standard therapy or without a suitable standard option receive oral CT3001 monotherapy, an investigational GPR35 inhibitor intended to suppress YAP signaling. Dose expansion is limited to patients with advanced colorectal cancer or pancreatic ductal adenocarcinoma.

ClinicalTrials.gov ID: NCT06598007

A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants With Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable advanced or metastatic MSI-H/dMMR solid tumors, generally after progression on anti-PD-(L)1 therapy, receive oral MOMA-341 alone or with irinotecan or an unspecified immunotherapy. MOMA-341 is an investigational covalent inhibitor of WRN helicase, which MSI-H/dMMR tumors depend on for DNA maintenance.

ClinicalTrials.gov ID: NCT06974110

A Phase 1 Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic NSCLC, colorectal cancer, or head and neck squamous cell carcinoma and ECOG performance status 0–1 receive JNJ-95437446, an investigational EGFR/MET-targeting antibody–drug conjugate that delivers an exatecan-derived topoisomerase I inhibitor. The study evaluates dose and safety; no human safety or efficacy results have been reported.

ClinicalTrials.gov ID: NCT07107230

A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, unresectable or metastatic solid tumors across multiple cohorts (e.g., gastric/EGJ, colorectal, pancreatic, sarcoma, mesothelioma, neuroendocrine, cutaneous/anal SCC, Merkel cell, MMR‑deficient/MSI cancers) after standard therapy, ECOG 0–1; stable small brain mets allowed. Treatment is autologous tumor-infiltrating lymphocyte (TIL) therapy (tumor harvest → ex vivo expansion) after cyclophosphamide/fludarabine lymphodepletion, followed by high-dose aldesleukin (IL-2) to support T-cell expansion; single course with option for a second.

ClinicalTrials.gov ID: NCT03935893

A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Optimization Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB365 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies With KRAS G12S or G12C Mutations

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic KRAS G12C- or G12S-mutated solid tumors and no curative treatment option receive weekly intravenous KQB365, an investigational inhibitor of mutant KRAS signaling. Combination and dose-optimization cohorts are limited to colorectal adenocarcinoma and evaluate KQB365 with cetuximab, an anti-EGFR antibody.

ClinicalTrials.gov ID: NCT06720987

Phase 1a/1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced mesothelin-associated solid tumors, ECOG performance status 0–1, and adequate organ function receive weekly intravenous CT-95 monotherapy. CT-95 is an investigational bispecific antibody that binds mesothelin on tumor cells and CD3 on T cells to promote tumor-cell killing.

ClinicalTrials.gov ID: NCT06756035

Phase I/ II Study of Pulmonary Suffusion to Control Minimal Residual Disease in Resectable or Ablatable Sarcoma or Colorectal Pulmonary Metastases

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with resectable or ablatable pulmonary metastases from soft tissue sarcoma, osteosarcoma, or colorectal cancer undergo regional isolated lung perfusion (“pulmonary suffusion”) with cisplatin followed by complete local control (metastasectomy/ablation), aiming to reduce intrapulmonary recurrence while limiting systemic toxicity. Eligible patients have ECOG 0–2 and adequate pulmonary function; bilateral disease may allow within-patient comparison of suffused vs non-suffused lungs.

ClinicalTrials.gov ID: NCT03965234